Agilent Technologies, Inc. (NYSE:A) Shares Acquired by Raymond James Trust N.A.

Raymond James Trust N.A. lifted its stake in Agilent Technologies, Inc. (NYSE:AFree Report) by 19.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,140 shares of the medical research company’s stock after buying an additional 662 shares during the period. Raymond James Trust N.A.’s holdings in Agilent Technologies were worth $576,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of A. Norges Bank purchased a new position in shares of Agilent Technologies during the 4th quarter valued at approximately $393,291,000. Victory Capital Management Inc. lifted its stake in Agilent Technologies by 939.8% during the third quarter. Victory Capital Management Inc. now owns 2,296,512 shares of the medical research company’s stock worth $256,796,000 after purchasing an additional 2,075,649 shares during the last quarter. Nordea Investment Management AB lifted its stake in Agilent Technologies by 233.7% during the fourth quarter. Nordea Investment Management AB now owns 2,666,416 shares of the medical research company’s stock worth $370,552,000 after purchasing an additional 1,867,377 shares during the last quarter. Morgan Stanley lifted its stake in Agilent Technologies by 79.4% during the fourth quarter. Morgan Stanley now owns 4,145,767 shares of the medical research company’s stock worth $620,414,000 after purchasing an additional 1,835,413 shares during the last quarter. Finally, Meritage Group LP bought a new position in Agilent Technologies during the third quarter worth $184,437,000.

Agilent Technologies Price Performance

A stock opened at $147.45 on Friday. The stock has a 50-day moving average price of $137.02 and a two-hundred day moving average price of $125.66. The stock has a market cap of $43.21 billion, a PE ratio of 35.11, a price-to-earnings-growth ratio of 4.50 and a beta of 1.11. The company has a current ratio of 2.68, a quick ratio of 2.04 and a debt-to-equity ratio of 0.41. Agilent Technologies, Inc. has a 1 year low of $96.80 and a 1 year high of $151.58.

Agilent Technologies (NYSE:AGet Free Report) last released its earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.07. The firm had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.59 billion. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. The company’s revenue was down 5.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.37 EPS. Equities analysts forecast that Agilent Technologies, Inc. will post 5.51 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 24th. Stockholders of record on Tuesday, April 2nd will be issued a $0.236 dividend. This represents a $0.94 annualized dividend and a dividend yield of 0.64%. The ex-dividend date is Monday, April 1st. Agilent Technologies’s payout ratio is 22.38%.

Insider Activity at Agilent Technologies

In related news, SVP Philip Binns sold 2,880 shares of the firm’s stock in a transaction dated Wednesday, December 27th. The shares were sold at an average price of $139.78, for a total value of $402,566.40. Following the completion of the sale, the senior vice president now directly owns 12,824 shares in the company, valued at approximately $1,792,538.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Agilent Technologies news, Director Heidi Fields sold 1,658 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total value of $239,315.72. Following the transaction, the director now directly owns 54,976 shares of the company’s stock, valued at approximately $7,935,235.84. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Philip Binns sold 2,880 shares of the company’s stock in a transaction on Wednesday, December 27th. The shares were sold at an average price of $139.78, for a total value of $402,566.40. Following the completion of the transaction, the senior vice president now directly owns 12,824 shares in the company, valued at $1,792,538.72. The disclosure for this sale can be found here. In the last ninety days, insiders sold 61,663 shares of company stock worth $9,205,804.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on A. Bank of America cut Agilent Technologies from a “buy” rating to a “neutral” rating and raised their price objective for the stock from $130.00 to $133.00 in a research note on Tuesday, December 12th. JPMorgan Chase & Co. increased their target price on Agilent Technologies from $140.00 to $165.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 20th. StockNews.com raised Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 19th. TheStreet raised Agilent Technologies from a “c+” rating to a “b-” rating in a research report on Friday, December 8th. Finally, Barclays raised their price target on Agilent Technologies from $120.00 to $125.00 and gave the company an “underweight” rating in a report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $141.31.

Check Out Our Latest Analysis on Agilent Technologies

Agilent Technologies Company Profile

(Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Featured Articles

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:AFree Report).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.